Barclays downgraded Reata Pharmaceuticals (RETA) to Equal Weight from Overweight with a price target of $172, up from $110. The analyst cites the announced acquisition by Biogen (BIIB) for the downgrade.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RETA:
- Biotech Alert: Searches spiking for these stocks today
- Reata Pharmaceuticals price target raised to $173 from $85 at Baird
- Reata Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
- Reata downgraded to Market Perform from Outperform at SVB Securities
- Reata Pharmaceuticals downgraded to Hold from Buy at Jefferies
